OmniBio Pharmaceutical, Inc. (OTCBB: OMBP) is a clinical‐stage bio pharmaceutical company that has licensed potential new therapies currently in development for an existing FDA approved drug -- Alpha‐1 Antitrypsin (AAT). OmniBio believes that the market opportunity for the use of AAT in treating Type 1 diabetes may exceed the current market.
The research and trials are being conducted by the University of Colorado, Denver and the Barbara Davis Center for Juvenile Diabetes, funded by OmniBio Pharmaceutical.
Connect with OmniBio:
News: http://OmniBioPharma.com
Facebook: http://goo.gl/ue8ou
LinkedIn: http://goo.gl/te3ly
Visit http://OmniBioPharma.com/investor-relations for SEC filings and additional information. Please refer to Safe Harbor statement at the end of the video.
OmniBio, part of the WestMountain Asset Management portfolio, is evaluating AAT for the treatment of several diseases, including Type 1 diabetes, bone marrow transplantation complications (also known as graft versus host disease or GVHD), islet transplantation, HIV, influenza and certain bacterial disorders, including anthrax exposure..
Connect with WestMountain Asset Management:
Facebook: http://WestMountainAM.com/FB
Twitter: http://WestMountainAM.com/TW
LinkedIn: http://WestMountainAM.com/LI
Blog: http://WestMountainAM.com/blog
If AAT is a powerful anti-inflammatory can a person use this to ease the pain associated with Osteoarthritis?
rmzllc 1 week ago